MGC Diagnostics Corporation Announces National Jewish Health Selects the Company as Preferred Provider for Cardiopulmonary Diagnostic Instrumentation
SAINT PAUL, Minn., Feb. 5, 2013 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology company, today announced that National Jewish Health has selected MGC Diagnostics as its preferred provider of cardiopulmonary diagnostic instrumentation. Based in Denver, Colorado, National Jewish Health is known worldwide for treatment of patients with respiratory, cardiac, immune and related disorders, and for groundbreaking medical research. National Jewish Health has been ranked by U.S.News & World Report as the number one respiratory hospital in the nation for the past 15 consecutive years. Founded in 1899 as a nonprofit hospital, National Jewish Health remains the only facility in the world dedicated exclusively to these disorders.
MGC Diagnostics has shipped a new fleet of cardiorespiratory devices; including body plethysmography, gas exchange and spirometer systems to the National Jewish Health main campus in Denver. Additionally, the Company is providing a comprehensive electronic medical interface, extending security and accessibility of cardiorespiratory patient data throughout the National Jewish Health network.
MGC Diagnostics, ranked 'Best-In-Class' over a two year trend by MD Buyline's User Satisfaction Report™, is focused on providing unmatched service and support, relentlessly making improvements, and anticipating and solving unmet needs.
Gregg O. Lehman , Ph.D., Chief Executive Officer and President of MGC Diagnostics, commented "MGC Diagnostics is pleased to have been selected by National Jewish Health, one of the world's leading medical research and treatment centers. We believe this win validates our technical innovation in cardiorespiratory health and our ability to provide leading medical facilities seamless communications with electronic medical records critical to improved workflows. We are excited to provide long term solutions that will assist them in maintaining their market leading status in respiratory care."
About National Jewish Health
National Jewish Health is known worldwide for treatment of patients with respiratory, cardiac, immune and related disorders, and for groundbreaking medical research. Founded in 1899 as a nonprofit hospital, National Jewish Health remains the only facility in the world dedicated exclusively to these disorders. Since 1998, U.S. News & World Report has ranked National Jewish Health the number one respiratory hospital in the nation.
About MGC Diagnostics
MGC Diagnostics Corporation (NASDAQ: MGCD), (formerly Angeion Corporation), is a global medical technology company dedicated to cardiorespiratory health solutions. MGC Diagnostics develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.